The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis Eric JutkowitzFernando Alarid-EscuderoHawre Jalal Practical Application 14 February 2019 Pages: 871 - 877
Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Xavier ArmoiryEwen CumminsHema Mistry Review Article 14 November 2018 Pages: 879 - 886
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Bram L. T. RamaekersRob RiemsmaManuela A. Joore Review Article Open access 14 November 2018 Pages: 887 - 894
A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective Steve RyderKathleen FoxJos Kleijnen Systematic Review 04 April 2019 Pages: 895 - 919
Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation Hui ShaoShuang YangLizheng Shi Original Research Article 19 February 2019 Pages: 921 - 929
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients Michelle TewPhilip ClarkeKim Dalziel Original Research Article 13 March 2019 Pages: 931 - 941
Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease Yawen JiangWeiyi Ni Original Research Article 14 March 2019 Pages: 943 - 952
The Cancer Drugs Fund in Practice and Under the New Framework Celia Sabry-GrantKinga MalottkiAlexander Diamantopoulos Original Research 03 April 2019 Pages: 953 - 962
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” R. Brett McQueenMelanie D. WhittingtonJonathan D. Campbell Letter to the Editor 02 May 2019 Pages: 963 - 964
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’ Holly GuyLydia WalderMark Fisher Letter to the Editor 02 May 2019 Pages: 965 - 967
Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? Paul Mark MitchellSridhar VenkatapuramJoanna Coast Correction Open access 09 March 2019 Pages: 969 - 969
Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial Baptiste LeurentManuel GomesJames R. Carpenter Correction Open access 09 March 2019 Pages: 971 - 971
Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities Edna KeeneyDalia DawoudSofia Dias Correction Open access 09 March 2019 Pages: 973 - 973
